Due: March 15, 2026 Twenty-first century air mobility demands twenty-first century technology. Join us for the MOSA Innovation Challenge, where more than 20 innovators will pitch cutting-edge communications, computing, and operations technologies to a distinguished Read More
Due: October 6, 2029 The purpose of this Notice of Funding Opportunity (NOFO) is to seek health services research grant applications focused on AHRQ research priorities, including improving healthcare quality and patient safety, improving healthcare Read More
Due: July 14, 2026 This Notice of Funding Opportunity (NOFO) encourages cooperative agreement applications for investigator-initiated, multi-site, clinical trials (Phase III and beyond) to study the effects of natural products (i.e. botanicals, probiotics, and products Read More
Due: March 1, 2024 Join the nation’s largest city-focused startup pitch program, showcasing hundreds of cutting-edge innovations addressing top urban challenges. Don’t miss this opportunity to pitch your solutions to leading city decision makers, investors, Read More
DUE: November 5, 2026 Furthering the science of personal health informatics by providing meaningful and actionable insights to individuals through innovative personal health data collection, integration, analysis, and personalized risk assessments and interpretation.
DUE: September 7, 2026 The National Cancer Institute invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
DUE: August 31, 2028 Funding opportunity to develop strategies and interventions to improve diagnostic safety in the heterogenous ambulatory care environment.
DUE: September 7, 2026 Seeking applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy.
DUE: January 7, 2027 Funding available to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.